

Richter and WhanIn signed a license and supply agreement for the commercialisation of cariprazine in South Korea

Budapest, Hungary – Seoul, South Korea – 02 March 2020 – Gedeon Richter Plc. (“Richter”) and WhanIn Pharm. Co., Ltd. (“WhanIn”) today announced the signing of an exclusive license and supply agreement to commercialize cariprazine, a novel antipsychotic in South Korea by WhanIn.

Under the terms of the agreement, Richter will be responsible for product supply and WhanIn will proceed with the registration, including a local clinical study necessary for the registration and commercialisation of the product in South Korea. According to IQVIA, sales for atypical antipsychotics in this market were USD 180 million for the 12 months 2019. Richter will receive from WhanIn an upfront payment. In addition, Richter will be entitled to sales related milestone payments on achievement of certain targets by WhanIn.

“Providing access to South Korean patients is an important step forward as we establish cariprazine as a global option in the treatment of schizophrenia and affective disorders. Based on its leadership and commercial experiences in the CNS area, we believe that WhanIn is the most suitable for advancing cariprazine in the Korean market,” said Mr Gábor Orbán, Chief Executive Officer of Richter.

Wonbum Lee, WhanIn’s Chief Executive Officer and President added “We are very pleased to establish this partnership with Richter to reinforce our portfolio of products and to strengthen our presence in the relevant therapeutic areas. We believe that cariprazine will meet the growing needs of patients and healthcare providers who require new and innovative treatment options.”

About cariprazine

Cariprazine is an oral, once daily atypical antipsychotic approved by the FDA for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, for the treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults and for the treatment of schizophrenia in adults. Apart from having been available on the US market for more than three years cariprazine is also approved in the EU for schizophrenia indication and has already been marketed in 15 European countries.

Cariprazine was discovered by scientists of Richter and was licensed out to Allergan in the United States. For more than a decade both companies have co-developed the molecule by conducting over 50 clinical trials enrolling thousands of patients worldwide to evaluate the efficacy and safety of cariprazine for people living with a broad range of mental health illnesses. While Gedeon Richter Plc markets the molecule on its own in Central-Eastern Europe, Western European marketing rights were licensed to Recordati and other license agreements have been signed with further strong local partners to ensure that cariprazine would be a treatment option to many patients globally suffering from these debilitating diseases.

About WhanIn

Established in 1978 under the foundation spirit “our development will contribute to a healthier society”, WhanIn develops, manufactures, markets, sells and exports therapeutic products with a social mission: “to keep the pain of disease away and seek for the value of life”.

WhanIn is a Korean stock-market listed company with about USD 130 million sales revenue estimated in 2018 and has been focusing on CNS products with an extensive market share, especially in the psychological area. Main products include anti-psychotics, anti-depressants, anti-epileptics, sedatives, anti-Parkinson’s and anti-dementia agents.

While focusing its capability on generating the maximum amount of added value, using systematic and specialized R&D and business activities, WhanIn has put its highest efforts to seek for new demands with the marketing strategy specialized in each field and to maximize customer satisfaction by providing various prescription drugs with the best quality.

WhanIn aims to become a global CNS specialized company by in licensing more innovative products and by developing new products with its own technology as well.

For more information, please visit www.whanin.com.

About Richter

Gedeon Richter Plc. (www.richter.hu), headquartered in Budapest / Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe, in China and in Latin America. Having reached a market capitalization of EUR 3.6 billion (USD 4.1 billion) by the end of 2019, Richter's consolidated sales were approximately EUR 1.6 billion (USD 1.7 billion) during the same year. The product portfolio of Richter covers many important therapeutic areas, including Women's Healthcare, Central Nervous System and Cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the Women's Healthcare field worldwide. Richter is also active in biosimilar product development.

Further information:

Richter:

| | |
|--------------------------|----------------|
| Katalin Ördög, Investors | +36 1 431 5680 |
| Zsuzsa Beke, Media | +36 1 431 4888 |

WhanIn:

| | |
|-------------------------------|----------------|
| Il Sub Kim, Investors & Media | +82 2 405 3063 |
|-------------------------------|----------------|